These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27651096)

  • 1. Beyond the hype and hope: Critical considerations for intranasal oxytocin research in autism spectrum disorder.
    Alvares GA; Quintana DS; Whitehouse AJ
    Autism Res; 2017 Jan; 10(1):25-41. PubMed ID: 27651096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising evidence and remaining issues regarding the clinical application of oxytocin in autism spectrum disorders.
    Yamasue H
    Psychiatry Clin Neurosci; 2016 Feb; 70(2):89-99. PubMed ID: 26394796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research.
    DeMayo MM; Song YJC; Hickie IB; Guastella AJ
    Paediatr Drugs; 2017 Oct; 19(5):391-410. PubMed ID: 28721467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxytocin and Autism Spectrum Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ooi YP; Weng SJ; Kossowsky J; Gerger H; Sung M
    Pharmacopsychiatry; 2017 Jan; 50(1):5-13. PubMed ID: 27574858
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism.
    Watanabe T; Kuroda M; Kuwabara H; Aoki Y; Iwashiro N; Tatsunobu N; Takao H; Nippashi Y; Kawakubo Y; Kunimatsu A; Kasai K; Yamasue H
    Brain; 2015 Nov; 138(Pt 11):3400-12. PubMed ID: 26336909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.
    Quintana DS; Westlye LT; Hope S; Nærland T; Elvsåshagen T; Dørum E; Rustan Ø; Valstad M; Rezvaya L; Lishaugen H; Stensønes E; Yaqub S; Smerud KT; Mahmoud RA; Djupesland PG; Andreassen OA
    Transl Psychiatry; 2017 May; 7(5):e1136. PubMed ID: 28534875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial.
    Kosaka H; Okamoto Y; Munesue T; Yamasue H; Inohara K; Fujioka T; Anme T; Orisaka M; Ishitobi M; Jung M; Fujisawa TX; Tanaka S; Arai S; Asano M; Saito DN; Sadato N; Tomoda A; Omori M; Sato M; Okazawa H; Higashida H; Wada Y
    Transl Psychiatry; 2016 Aug; 6(8):e872. PubMed ID: 27552585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism.
    Parker KJ; Oztan O; Libove RA; Sumiyoshi RD; Jackson LP; Karhson DS; Summers JE; Hinman KE; Motonaga KS; Phillips JM; Carson DS; Garner JP; Hardan AY
    Proc Natl Acad Sci U S A; 2017 Jul; 114(30):8119-8124. PubMed ID: 28696286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis.
    Huang Y; Huang X; Ebstein RP; Yu R
    Neurosci Biobehav Rev; 2021 Mar; 122():18-27. PubMed ID: 33400920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder.
    Cai Q; Feng L; Yap KZ
    Psychiatry Clin Neurosci; 2018 Mar; 72(3):140-151. PubMed ID: 29232031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of oxytocin administration on individuals with ASD: Neuroimaging and behavioral evidence.
    Baker E; Stavropoulos KKM
    Prog Mol Biol Transl Sci; 2020; 173():209-238. PubMed ID: 32711811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Potential of Nasal Oxytocin Administration for Remediation of Autism Spectrum Disorders.
    Okamoto Y; Ishitobi M; Wada Y; Kosaka H
    CNS Neurol Disord Drug Targets; 2016; 15(5):564-77. PubMed ID: 27071789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial.
    Guastella AJ; Gray KM; Rinehart NJ; Alvares GA; Tonge BJ; Hickie IB; Keating CM; Cacciotti-Saija C; Einfeld SL
    J Child Psychol Psychiatry; 2015 Apr; 56(4):444-52. PubMed ID: 25087908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B).
    Spanos M; Chandrasekhar T; Kim SJ; Hamer RM; King BH; McDougle CJ; Sanders KB; Gregory SG; Kolevzon A; Veenstra-VanderWeele J; Sikich L
    Contemp Clin Trials; 2020 Nov; 98():106103. PubMed ID: 32777383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxytocin and Autism Spectrum Disorders.
    Yamasue H; Domes G
    Curr Top Behav Neurosci; 2018; 35():449-465. PubMed ID: 28766270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Possible Role of Oxytocin in Autism Spectrum Disorder].
    Munesue T; Minabe Y
    Seishin Shinkeigaku Zasshi; 2016; 118(6):399-409. PubMed ID: 30620499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.
    Yamasue H; Okada T; Munesue T; Kuroda M; Fujioka T; Uno Y; Matsumoto K; Kuwabara H; Mori D; Okamoto Y; Yoshimura Y; Kawakubo Y; Arioka Y; Kojima M; Yuhi T; Owada K; Yassin W; Kushima I; Benner S; Ogawa N; Eriguchi Y; Kawano N; Uemura Y; Yamamoto M; Kano Y; Kasai K; Higashida H; Ozaki N; Kosaka H
    Mol Psychiatry; 2020 Aug; 25(8):1849-1858. PubMed ID: 29955161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.
    Yatawara CJ; Einfeld SL; Hickie IB; Davenport TA; Guastella AJ
    Mol Psychiatry; 2016 Sep; 21(9):1225-31. PubMed ID: 26503762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal oxytocin administration ameliorates social behavioral deficits in a POGZ
    Kitagawa K; Matsumura K; Baba M; Kondo M; Takemoto T; Nagayasu K; Ago Y; Seiriki K; Hayata-Takano A; Kasai A; Takuma K; Hashimoto R; Hashimoto H; Nakazawa T
    Mol Brain; 2021 Mar; 14(1):56. PubMed ID: 33726803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies.
    Althammer F; Muscatelli F; Grinevich V; Schaaf CP
    Transl Psychiatry; 2022 Aug; 12(1):318. PubMed ID: 35941105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.